Markus Puhlmann Biography and Net Worth

Chief Medical Officer of Perspective Therapeutics

A clinical researcher with over 30 years of combined experience in healthcare and the pharmaceutical industry with leadership positions in oncology drug development.

What is Markus Puhlmann's net worth?: The estimated net worth of Markus Puhlmann is at least $328.73 thousand as of January 24th, 2024. Dr. Puhlmann owns 137,542 shares of Perspective Therapeutics stock worth more than $328,725 as of December 4th. This net worth approximation does not reflect any other investments that Dr. Puhlmann may own. Additionally, Dr. Puhlmann receives an annual salary of $633,140.00 as Chief Medical Officer at Perspective Therapeutics. Learn More about Markus Puhlmann's net worth.
How old is Markus Puhlmann?: Dr. Puhlmann is currently 58 years old. There are 2 older executives and no younger executives at Perspective Therapeutics. Learn More on Markus Puhlmann's age.
What is Markus Puhlmann's salary?: As the Chief Medical Officer of Perspective Therapeutics, Inc., Dr. Puhlmann earns $633,140.00 per year. There are 2 executives that earn more than Dr. Puhlmann. The highest earning executive at Perspective Therapeutics is Mr. Jonathan R. Hunt, CFO and Principal Financial & Accounting Officer, who commands a salary of $944,350.00 per year. Learn More on Markus Puhlmann's salary.
How do I contact Markus Puhlmann?: The corporate mailing address for Dr. Puhlmann and other Perspective Therapeutics executives is 2401 Elliott Avenue, Suite 320, Seattle, WA 98121, United States. Perspective Therapeutics can also be reached via phone at 206-676-0900 and via email at [email protected]. Learn More on Markus Puhlmann's contact information.
Has Markus Puhlmann been buying or selling shares of Perspective Therapeutics?: Markus Puhlmann has not been actively trading shares of Perspective Therapeutics during the last quarter. Most recently, on Wednesday, January 24th, Markus Puhlmann bought 28,000 shares of Perspective Therapeutics stock. The stock was acquired at an average cost of $5.00 per share, with a total value of $140,000.00. Following the completion of the transaction, the insider now directly owns 137,542 shares of the company's stock, valued at $687,710. Learn More on Markus Puhlmann's trading history.
Who are Perspective Therapeutics' active insiders?: Perspective Therapeutics' insider roster includes Juan Graham (CFO), Heidi Henson (Director), Jonathan Hunt (CFO), Markus Puhlmann (Chief Medical Officer), Johan Spoor (CEO), Robert Williamson, III (Director), and Lori Woods (Director). Learn More on Perspective Therapeutics' active insiders.
Are insiders buying or selling shares of Perspective Therapeutics?: In the last twelve months, Perspective Therapeutics insiders bought shares 8 times. They purchased a total of 170,169 shares worth more than $428,783.18. The most recent insider tranaction occured on November, 13th when CAO Jonathan Robert Hunt bought 11,000 shares worth more than $22,330.00. Insiders at Perspective Therapeutics own 3.7% of the company. Learn More about insider trades at Perspective Therapeutics.
Information on this page was last updated on 11/13/2025.

Markus Puhlmann Insider Trading History at Perspective Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/24/2024	Buy	28,000	$5.00	$140,000.00	137,542
12/18/2023	Buy	6,041	$2.60	$15,706.60	69,542
12/15/2023	Buy	13,500	$2.70	$36,450.00	63,500

Markus Puhlmann Buying and Selling Activity at Perspective Therapeutics

Perspective Therapeutics Company Overview

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

Today's Range

Now: $2.39

$2.17

$2.41

50 Day Range

MA: $2.94

$2.05

$4.98

2 Week Range

Now: $2.39

$1.60

$5.39

Volume

1,930,567 shs

Average Volume

1,946,208 shs

Market Capitalization

$177.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22

Markus Puhlmann Biography and Net Worth

What is Markus Puhlmann's net worth?

How old is Markus Puhlmann?

What is Markus Puhlmann's salary?

How do I contact Markus Puhlmann?

Has Markus Puhlmann been buying or selling shares of Perspective Therapeutics?

Who are Perspective Therapeutics' active insiders?

Are insiders buying or selling shares of Perspective Therapeutics?